Combo therapy does not affect COPD death rate, but improves breathing, report finds

Share this article:

The use of a steroid-plus-bronchodilator won't lower the death risk for patients with chronic obstructive pulmonary disease, but it will likely improve quality of life, according to new research results.

There was no notable difference in the mortality of COPD suffers who used Advair, an inhaled steroid combined with a long-acting bronchodilator, versus those given a placebo, according to researchers at the University of Liverpool and University Hospital Aintree. But researchers who studied more than 6,100 people with the condition noticed a 25% decline in breathing and health problems associated with the progressive, debilitating lung disease.

Study participants were randomly assigned the use of the long-acting bronchodilator salmeterol alone, the inhaled steroid fluticasone propionate alone, salmeterol plus fluticasone in combination (sold as Advair), or a placebo.

The full study appears in the New England Journal of Medicine.
Share this article:

More in News

Breier named new CEO at Kindred

Breier named new CEO at Kindred

Kindred Healthcare announced Thursday that it has chosen a new top executive to lead its push toward creating a mammoth national brand. Benjamin A. Breier, the company's current president and ...

Proposed managed care rule could accelerate shift away from nursing home care, official suggests

Proposed managed care rule could accelerate shift away ...

Proposed regulations slated for early 2015 likely will affect how Medicaid managed care balances home- versus facility-based long-term care, news sources reported Wednesday.

Assisted living residents say 'homelike' setting not so important

Contrary to conventional wisdom, assisted living residents might not place a high value on how "homelike" their surroundings are, suggest findings out of St. Catherine University in St. Paul, MN.